Hypofractionated Preoperative Radiation for Head and Neck Cancers (HyPR-HN)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05538533|
Recruitment Status : Recruiting
First Posted : September 14, 2022
Last Update Posted : March 3, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Head and Neck Cancer||Radiation: 46 Gy Radiation Therapy Radiation: 40 Gy Radiation Therapy Radiation: 35 Gy Radiation Therapy||Not Applicable|
All subjects in this study will receive hypofractionated adjuvant radiation therapy, which will be subject to fractionation reduction, that being 10 fractions, 7 fractions, or 5 fractions, as compared to 30 fractions of conventional radiation therapy.
The subjects will receive smaller number of fractions (total visits) but with a higher dose of radiation. Participants will receive a total radiation dose of 46 Gy in 10 fractions (Dose Level 1), 40 Gy in 7 fractions (Dose Level 2), or 35 Gy in 5 fractions (Dose Level 3), depending on the assigned experimental total fractions. Radiation will be delivered using intensity modulated radiation therapy (IMRT) with a daily cone-beam CT for five days a week, for less than two weeks depending on the assigned dose level at the time of enrollment.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||18 participants|
|Intervention Model:||Sequential Assignment|
|Intervention Model Description:||This study will use a time-to-event continual reassessment method (TITE-CRM) for assigning subjects to the radiation therapy dosages.|
|Masking:||None (Open Label)|
|Official Title:||A Phase I Study of Hypofractionated Preoperative Radiation for Head and Neck Cancers (HyPR-HN)|
|Actual Study Start Date :||January 6, 2023|
|Estimated Primary Completion Date :||December 2024|
|Estimated Study Completion Date :||December 2025|
Experimental: 46 Gray (Gy)
46 gy of radiation therapy will be administered in 10 fractions.
Radiation: 46 Gy Radiation Therapy
Dose per fraction of 4.6.
Experimental: 40 Gray (Gy)
40 gy of radiation therapy will be administered in 7 fractions.
Radiation: 40 Gy Radiation Therapy
Dose per fraction 5.7.
Experimental: 35 Gray (Gy)
35 gy of radiation therapy will be administered in 5 fractions.
Radiation: 35 Gy Radiation Therapy
Dose per fraction 7.0.
- The number of subjects with a dose-limiting toxicity related to inoperability. [ Time Frame: 8 Weeks ]Inoperability after HyPR-HN, is defined as an inability to proceed to surgery within eight weeks of radiation.
- The number of subjects with a dose-limiting toxicity related to perioperative complication rates. [ Time Frame: 8 Weeks ]Severe perioperative complication rates, defined as unacceptable toxicity from initiation of treatment until 30 days postoperatively (grade 4/5 toxicity) probably or definitely related to treatment.
- The number of subjects with severe delayed toxicity. [ Time Frame: Up to one year ]Severe delayed toxicities, defined as any unacceptable toxicity (grade 4+) after 30 days postoperatively until one year after initiation of HyPR-HN probably or definitely related to treatment.
- Overall survival [ Time Frame: One year ]This measure is the number of subjects alive at one year following the conclusion of scheduled radiation therapy.
- Recurrence-free Survival [ Time Frame: One year ]This measure is the number of subjects who are survival free of locoregional recurrence or distant metastasis.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
Patients 18 years or older with surgically resectable, Human papillomavirus (HPV) -negative squamous cell carcinoma of the head and neck (squamous cell carcinoma of the larynx, hypopharynx, oropharynx, oral cavity, nasal cavity or paranasal sinuses). Resectability will be determined by the treating surgeon. Patients must have locoregionally advanced disease defined by clinical T3-4 staging and/or clinical node positive staging. Patients may also be eligible if they meet one of the following criteria:
- Clinical T2N0 disease with perineural invasion identified on a pretreatment biopsy.
- Clinical T2N0 disease with lymphovascular space invasion identified on a pretreatment biopsy.
- Clinical T2N0 oral cavity cancer with clinical, biopsy, or radiographic depth of invasion of at least 5 mm.
- Zubrod performance status 0-2.
- Patients must have the psychological ability and general health that permits completion of the study requirements and required follow-up.
- Inclusion of COVID-19 positive patients will be based on standard institutional protocol.
Female patients must meet one of the following:
- Postmenopausal for at least one year before the screening visit, OR
- Surgically sterile (i.e., undergone a hysterectomy or bilateral oophorectomy), OR
- If subject is of childbearing potential (defined as not satisfying either of the above two criteria), agrees to practice two acceptable methods of contraception (combination methods require use of two of the following: diaphragm with spermicide, cervical cap with spermicide, contraceptive sponge, male or female condom, hormonal contraceptive) from the time of signing of the informed consent form through 90 days after the last dose of study agent, AND
- Agrees to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptom-thermal, postovulation methods] and withdrawal are not acceptable contraception methods).
Male patients, even if surgically sterilized (i.e., status post vasectomy), must agree to one of the following:
- Practice effective barrier contraception during the entire study period and through 60 calendar days after the last dose of study agent, OR
- Must also adhere to the guidelines of any study-specific pregnancy prevention program, if applicable, OR
- Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptom-thermal, postovulation methods] and withdrawal are not acceptable methods of contraception.
- Ability to understand a written informed consent document, and the willingness to sign it.
- Radiographic evidence of extranodal extension.
- Patients with laryngeal involvement who are candidates for non-surgical laryngeal preservation as deemed by a surgeon and/or radiation oncologist. These patients include, but are not limited to, those with T1-T3 laryngeal cancer who do not have pretreatment tracheostomy and/or feeding tube or those with base of tongue/hypopharyngeal cancers with laryngeal involvement without cartilage invasion or pretreatment tracheostomy and/or feeding tube.
- HPV-positive squamous cell carcinoma.
- Prior invasive malignancy within the past three years (except for non-melanomatous skin cancer, and early stage treated prostate cancer).
- Life expectancy less than 12 months.
- Zubrod performance status ≥ 3.
- Patients with prior radiation therapy to the head and neck (Note: Prior external beam radiotherapy is excluded, but iodine-131 is allowed).
- Prior systemic therapy, including cytotoxic chemotherapy, biologic/targeted therapy, or immune therapy for the study cancer.
- Body weight ≤ 30 kg.
- Any of the following severe laboratory abnormalities within 14 days of registration, unless corrected prior to it: sodium < 130 mmol/L or > 155 mmol/L; potassium < 3.5 mmol/L or > 6 mmol/L; fasting glucose < 40 mg/dL or > 400 mg/dL; serum calcium (ionized or adjusted for albumin) < 7 mg/dL or > 12.5 mg/dL; magnesium < 0.9 mg/dL or > 3 mg/dL.
- Unstable angina and/or congestive heart failure requiring hospitalization within three months prior to step 1 registration.
- Transmural myocardial infarction within three months prior to step 1 registration.
- Medical or psychiatric illness which would compromise the patient's ability to tolerate treatment or limit compliance with study requirements.
- Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception during treatment and for six months after radiation, this exclusion is necessary because the treatment involved in this study may be significantly teratogenic. Women who are breastfeeding are also excluded.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05538533
|Contact: Medical College of Wisconsin Cancer Center Clinical Trials Office||866-680-0505 ext email@example.com|
|United States, Wisconsin|
|Froedtert Hospital and the Medical College of Wisconsin||Recruiting|
|Milwaukee, Wisconsin, United States, 53226|
|Contact: Medical College of Wisconsin Cancer Center Clinical Trials Office 866-680-0505 ext 8900 firstname.lastname@example.org|
|Contact: Joseph Zenga, MD email@example.com|
|Principal Investigator: Joseph Zenga, MD|
|Principal Investigator:||Joseph Zenga, MD||Medical College of Wisconsin|
|Responsible Party:||Joseph Zenga, Assistant Professor, Medical College of Wisconsin|
|Other Study ID Numbers:||
|First Posted:||September 14, 2022 Key Record Dates|
|Last Update Posted:||March 3, 2023|
|Last Verified:||March 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||Yes|
|Product Manufactured in and Exported from the U.S.:||No|
Head and Neck Cancer
Hypofractionated Preoperative Radiation
Time-to-Event Continuous Reassessment Methodology
Head and Neck Neoplasms
Neoplasms by Site